Retatrutide Half-Life and Pharmacokinetics

Retatrutide has a half-life of approximately 6 days, enabling once-weekly dosing. This is achieved through a fatty diacid conjugation that promotes albumin binding — the same class of engineering used by semaglutide (~7-day half-life) and tirzepatide (~5-day half-life).

This article covers what the Phase 1 data shows about how retatrutide moves through the body, how long it lasts, and how it compares to other GLP-1 drugs.

Key Pharmacokinetic Numbers

Data from the Phase 1 single-ascending-dose study in healthy volunteers and the Phase 1b multiple-ascending-dose study in adults with type 2 diabetes.

How Once-Weekly Dosing Is Achieved

Native GLP-1 hormone has a half-life of only 2 minutes — it is rapidly broken down by the DPP-4 enzyme. Retatrutide extends this to 6 days through three key molecular modifications:

Fatty Diacid Conjugation

Retatrutide is a 39-amino-acid peptide conjugated to a C20 fatty diacid at position K4 (lysine-4), connected through an AEEA spacer and gamma-glutamic acid linker. This fatty acid chain binds non-covalently to serum albumin in the bloodstream, which:

1. Protects the peptide from enzymatic degradation
2. Creates a circulating reservoir — the drug slowly releases from albumin into the free (active) form
3. Slows renal clearance — the albumin-drug complex is too large for kidney filtration
4. Provides sustained release — free retatrutide is continuously replenished from the albumin-bound pool

DPP-4 Resistance

An alpha-amino isobutyric acid (Aib) residue at position 2 makes retatrutide resistant to cleavage by the DPP-4 enzyme, which would otherwise degrade it within minutes.

Optimized Receptor Binding

An Aib residue at position 20 optimizes GIP receptor activity and the pharmacokinetic profile. Alpha-methyl-L-leucine at position 13 promotes optimal binding across all three receptors.

Absorption and Distribution

After subcutaneous injection, retatrutide is absorbed through local blood vessels and the lymphatic system at the injection site. The albumin-binding fatty diacid ensures slow, sustained absorption.

• Peak concentration (Tmax): 12–72 hours post-dose in healthy volunteers; 12–48 hours (median) in adults with type 2 diabetes
• Dose proportionality: Plasma concentrations, AUC, and Cmax increase proportionally with dose — dose adjustments produce predictable changes in drug levels
• Steady state: Reached after approximately 4–5 weeks of consistent weekly dosing (4–5 half-lives), which is why the clinical titration schedule uses 4-week intervals at each dose level

Metabolism and Elimination

Retatrutide is primarily eliminated through proteolytic degradation, consistent with other peptide drugs. The liver and kidneys both contribute to the elimination process. Importantly, retatrutide does not interact with cytochrome P450 enzymes, which means it has minimal risk of drug-drug interactions through that pathway.

Half-Life Comparison: Triple vs Dual vs Single Agonist

All three drugs use fatty acid acylation to achieve albumin binding and extended half-lives suitable for once-weekly dosing. The pharmacokinetic profiles are broadly comparable — the clinical efficacy differences between these drugs are driven by receptor pharmacology (triple vs dual vs mono agonism), not by pharmacokinetic differences.

What the Phase 1 Data Showed

Phase 1 Single-Ascending-Dose Study (Coskun et al., 2022)

Forty-seven healthy volunteers received single doses. The study established the ~6-day half-life, dose-proportional pharmacokinetics, and the 12–72 hour Tmax window.

Phase 1b Multiple-Ascending-Dose Study (Urva et al., Lancet 2022)

Adults with type 2 diabetes received weekly doses over 12 weeks at 0.5 mg, 1.5 mg, 3 mg, 3/6 mg (escalating), and 3/6/9/12 mg (escalating), with placebo and dulaglutide 1.5 mg as comparators.

Key findings:

• Pharmacokinetics were dose proportional
• Steady-state exposures were maintained with once-weekly dosing
• Body weight reduction was dose-dependent: up to -8.96 kg in the highest dose group vs placebo at 12 weeks
• HbA1c reductions of -0.4% to -1.2% across dose groups
• Safety profile consistent with other incretin drugs (GI adverse events most common)

Frequently Asked Questions

Sources

• Coskun, T., et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss. Cell Metabolism. DOI: 10.1016/j.cmet.2022.07.013.
• Urva, S., et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. DOI: 10.1016/S0140-6736(22)02033-5.
• Min, T., et al. (2025). A comprehensive review on the pharmacokinetics and drug-drug interactions of GLP-1 receptor agonists. Drug Design, Development and Therapy. DovePress.

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the FDA.

Do not use this information to make decisions about your health without consulting a qualified healthcare provider.

This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.